© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Effect of the Methylenetetrahydrofolate Reductase C677T Polymorphism on Chemosensitivity of Colon and Breast Cancer Cells to 5-Fluorouracil and Methotrexate
Affiliations of authors: Department of Medicine (KJS, YIK), Department of Nutritional Sciences (YIK), University of Toronto, Toronto, Ontario, Canada; Clinical Epidemiology Unit, Sunnybrook and Women's College Health Sciences Center, Toronto (RC); Academic Unit of Paediatrics and Obstetrics and Gynaecology, University of Leeds, West Yorkshire, U.K. (ZY); Department of Human Nutrition, School of Applied Sciences, Ourimbah Campus, University of Newcastle, Australia, New South Wales (ML); Division of Gastroenterology, Department of Medicine, St. Michael's Hospital, Toronto (YIK).
Correspondence to: Young-In Kim, MD, Medical Sciences Building, Rm. 7258, University of Toronto, 1 King's College Circle, Toronto, Ontario, Canada M5S 1A8 (e-mail: youngin.kim{at}utoronto.ca)
Background: Although single nucleotide polymorphisms may be potentially important pharmacogenetic determinants of cancer therapy, functional evidence regarding their relevance is currently lacking. The C677T polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene is associated with changes in cellular composition of folates. We hypothesized that this polymorphism may modulate the cytotoxic effect of 5-fluorouracil (5FU) and methotrexate (MTX), two commonly used chemotherapeutic agents for colon and breast cancers, because the modes of action of 5FU and MTX are critically dependent on cellular composition of folates. Methods: Human HCT116 colon and MDA-MB-435 breast cancer cells were stably transfected with wild-type or mutant 677T human MTHFR cDNA. MTHFR enzyme activity and thermolability, intracellular folate composition, growth rate, and catalytic thymidylate synthase activity were determined. In vitro chemosensitivity to 5FU and MTX was determined using the sulforhodamine B assay. In vivo chemosensitivity of HCT116 cells to 5FU was determined in nude mice. Results: Compared with cells expressing the wild-type MTHFR, HCT116 and MDA-MB-435 cells expressing the mutant 677T MTHFR had decreased MTHFR activity, MTHFR thermolability, changed intracellular folate distribution, accelerated cellular growth rate, and increased thymidylate synthase activity. The MTHFR 677T mutation increased chemosensitivity of colon and breast cancers to 5FU, but decreased chemosensitivity of breast cancer cells to MTX. In nude mice, xenografts expressing the mutant 677T MTHFR grew faster, but were more sensitive to 5FU, than xenografts expressing the wild-type protein. Conclusions: Our data provide evidence that the MTHFR C677T polymorphism affects the concentration and intracellular distribution of folates and changes the growth and chemosensitivity of colon and breast cancer cells. The MTHFR C677T polymorphism may be a useful pharmacogenetic determinant for providing rational and effective tailored chemotherapy.
This article has been cited by other articles:
![]() |
R. Sharma, J. M. Hoskins, L. P. Rivory, M. Zucknick, R. London, C. Liddle, and S. J. Clarke Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients Clin. Cancer Res., February 1, 2008; 14(3): 817 - 825. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Cho, P. D. Cole, K.-J. Sohn, G. Gaisano, R. Croxford, B. A. Kamen, and Y.-I. Kim Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells Mol. Cancer Ther., November 1, 2007; 6(11): 2909 - 2920. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ruzzo, F. Graziano, F. Loupakis, E. Rulli, E. Canestrari, D. Santini, V. Catalano, R. Ficarelli, P. Maltese, R. Bisonni, et al. Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy J. Clin. Oncol., April 1, 2007; 25(10): 1247 - 1254. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Hayashi, K.-J. Sohn, J. M. Stempak, R. Croxford, and Y.-I. Kim Folate Deficiency Induces Cell-Specific Changes in the Steady-State Transcript Levels of Genes Involved in Folate Metabolism and 1-Carbon Transfer Reactions in Human Colonic Epithelial Cells J. Nutr., March 1, 2007; 137(3): 607 - 613. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ruzzo, F. Graziano, K. Kawakami, G. Watanabe, D. Santini, V. Catalano, R. Bisonni, E. Canestrari, R. Ficarelli, E. T. Menichetti, et al. Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy J. Clin. Oncol., April 20, 2006; 24(12): 1883 - 1891. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Z Stolzenberg-Solomon, S.-C. Chang, M. F Leitzmann, K. A Johnson, C. Johnson, S. S Buys, R. N Hoover, and R. G Ziegler Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am. J. Clinical Nutrition, April 1, 2006; 83(4): 895 - 904. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. de Jonge, J. H. Hooijberg, B. D. van Zelst, G. Jansen, C. H. van Zantwijk, G. J. L. Kaspers, F. G. J. Peters, Y. Ravindranath, R. Pieters, and J. Lindemans Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia Blood, July 15, 2005; 106(2): 717 - 720. [Abstract] [Full Text] [PDF] |
||||
![]() |
P Ranganathan, Y Berkun, G Friedman, and A Ben-Yehuda Methotrexate related adverse effects in patients with RA * Authors' reply Ann Rheum Dis, June 1, 2005; 64(6): 968 - 968. [Full Text] [PDF] |
||||
![]() |
L. Le Marchand, L. R. Wilkens, L. N. Kolonel, and B. E. Henderson The MTHFR C677T Polymorphism and Colorectal Cancer: The Multiethnic Cohort Study Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1198 - 1203. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jakobsen, J. N. Nielsen, N. Gyldenkerne, and J. Lindeberg Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphism in Normal Tissue As Predictors of Fluorouracil Sensitivity J. Clin. Oncol., March 1, 2005; 23(7): 1365 - 1369. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. P. Quinlivan, S. R. Davis, K. P. Shelnutt, G. N. Henderson, H. Ghandour, B. Shane, J. Selhub, L. B. Bailey, P. W. Stacpoole, and J. F. Gregory III Methylenetetrahydrofolate Reductase 677C->T Polymorphism and Folate Status Affect One-Carbon Incorporation into Human DNA Deoxynucleosides J. Nutr., March 1, 2005; 135(3): 389 - 396. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Stankova, J. Shang, and R. Rozen Antisense Inhibition of Methylenetetrahydrofolate Reductase Reduces Cancer Cell Survival In vitro and Tumor Growth In vivo Clin. Cancer Res., March 1, 2005; 11(5): 2047 - 2052. [Abstract] [Full Text] [PDF] |
||||
![]() |
K-J Sohn, F Smirnakis, D N Moskovitz, P Novakovic, Z Yates, M Lucock, R Croxford, and Y-I Kim Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate Gut, December 1, 2004; 53(12): 1825 - 1831. [Abstract] [Full Text] [PDF] |
||||








